A hydroxamic acid thrombospondin peptide analog that inhibits aggrecanase activity
CA 2453346 A1 · Owner: Mp Biomedicals, Inc. · Inventors: Wang, Jinhai; Tortorella, Michael; Balhorn, Rodney L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention concerns the generation of hydroxamic acid thrombospondin-peptide analogs that inhibit aggrecanase activity. These analogs are useful in the treatment of diseases characterized by cartilage degradation, such as osteoarthritis, rheumatoid arthritis spondylarthropathies, and septic arthritis. The invention describes a novel small molecule, enzyme inhibitor that binds both the enzyme and its naturally occurring substrate.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 9, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended July 9, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 9, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.